Genomma Lab Internacional Stock Gross Profit
Genomma Lab Internacional fundamentals help investors to digest information that contributes to Genomma Lab's financial success or failures. It also enables traders to predict the movement of Genomma Pink Sheet. The fundamental analysis module provides a way to measure Genomma Lab's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genomma Lab pink sheet.
Genomma |
Genomma Lab Internacional Company Gross Profit Analysis
Genomma Lab's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Genomma Lab Gross Profit | 9.56 B |
Most of Genomma Lab's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genomma Lab Internacional is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Genomma Lab Internacional reported 9.56 B of gross profit. This is 326.32% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The gross profit for all United States stocks is 65.07% higher than that of the company.
Genomma Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genomma Lab's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genomma Lab could also be used in its relative valuation, which is a method of valuing Genomma Lab by comparing valuation metrics of similar companies.Genomma Lab is currently under evaluation in gross profit category among its peers.
Genomma Fundamentals
Return On Equity | 0.13 | |||
Return On Asset | 0.0921 | |||
Profit Margin | 0.08 % | |||
Operating Margin | 0.20 % | |||
Current Valuation | 1.09 B | |||
Shares Outstanding | 1 B | |||
Shares Owned By Insiders | 29.00 % | |||
Shares Owned By Institutions | 29.10 % | |||
Price To Earning | 11.09 X | |||
Price To Book | 1.38 X | |||
Price To Sales | 0.05 X | |||
Revenue | 15.49 B | |||
Gross Profit | 9.56 B | |||
EBITDA | 2.84 B | |||
Net Income | 1.31 B | |||
Cash And Equivalents | 1.3 B | |||
Cash Per Share | 1.30 X | |||
Total Debt | 3.83 B | |||
Debt To Equity | 0.51 % | |||
Current Ratio | 1.67 X | |||
Book Value Per Share | 10.98 X | |||
Cash Flow From Operations | 1.47 B | |||
Earnings Per Share | 0.07 X | |||
Number Of Employees | 2.3 K | |||
Beta | 0.53 | |||
Market Capitalization | 973.77 M | |||
Total Asset | 21.54 B | |||
Annual Yield | 0.05 % | |||
Net Asset | 21.54 B | |||
Last Dividend Paid | 0.38 |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Genomma Pink Sheet
If you are still planning to invest in Genomma Lab Internacional check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomma Lab's history and understand the potential risks before investing.
CEOs Directory Screen CEOs from public companies around the world | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |